Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Previously submitted to: JMIR Public Health and Surveillance (no longer under consideration since Oct 17, 2023)

Date Submitted: Feb 7, 2023

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

The Efficacy and Safety of Hydroxychloroquine for COVID-19 Prophylaxis: Systematic Review and Meta-analysis

  • Juntao Yin; 
  • Yang Li; 
  • Chaoyang Wang; 
  • Changjiang Qin; 
  • Mingsan Miao

ABSTRACT

Background:

The efficacy and safety of hydroxychloroquine (HCQ) for COVID-19 prophylaxis remains highly controversial.

Objective:

This study aimed to evaluate the efficacy and safety of HCQ to prevent COVID-19.

Methods:

Electronic searches were conducted up to December 21, 2022 in Pubmed/MEDLINE, Embase, medRxiv, the Cochrane COVID-19 Register of Controlled Trials, clinicaltrials.gov, and the WHO International Clinical Trials Registry Platform. The primary outcomes included COVID-19 transmission, and mortality. Treatment effects were reported as relative risk (RR) for dichotomous variables with 95% confidence intervals (CI). We performed either a fixed- or random-effects model to pool the results of individual studies depending on the presence of heterogeneity.

Results:

Fifteen randomized trials were included: 10 pre-exposure prophylaxis trials and 5 post-exposure prophylaxis trials. The pooled RR of COVID-19 transmission in the pre-exposure prophylaxis trials was 0.73 (95% CI 0.66-0.81) when using either a fixed-effect model. The pooled RR of COVID-19 transmission in the post-exposure prophylaxis trials was 0.93 (95% CI 0.76-1.15). The final pooled RR, including all pre- and post-exposure trials, was 0.78 (95% CI 0.74-0.86).

Conclusions:

Available evidence suggested that prophylactic HCQ for people at risk of exposure to SARS-CoV-2 was safe and effective. Therefore, HCQ as prophylaxis (especially as pre-exposure prophylaxis) for COVID-19 is recommended. Clinical Trial: PROSPERO (Prospective International Register of Systematic Reviews) CRD42022357880; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=257299


 Citation

Please cite as:

Yin J, Li Y, Wang C, Qin C, Miao M

The Efficacy and Safety of Hydroxychloroquine for COVID-19 Prophylaxis: Systematic Review and Meta-analysis

JMIR Preprints. 07/02/2023:46323

DOI: 10.2196/preprints.46323

URL: https://preprints.jmir.org/preprint/46323

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.